Seattle Genetics to acquire biotech company for $614m

Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi to acquire Ablynx for €3.9bn

29 January 2018 Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).

Asia-Pacific

Allergan to buy Australian tissue repair company for $95m

12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

Big Pharma

Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute

14 November 2019 Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.

More on this story

Big Pharma

Sanofi to acquire Ablynx for €3.9bn

29 January 2018 Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).

Asia-Pacific

Allergan to buy Australian tissue repair company for $95m

12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

Big Pharma

Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute

More on this story

Big Pharma

Sanofi to acquire Ablynx for €3.9bn

29 January 2018 Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).

Asia-Pacific

Allergan to buy Australian tissue repair company for $95m

12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

Big Pharma

Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute